7Baggers
 Atossa Therapeutics appoints Janet Rea as SVP of R&D  Investing.com Wed, 01 Oct 2025 22:57:21 GMT
 Atossa Therapeutics Releases Updated Corporate Presentation  TipRanks Fri, 26 Sep 2025 21:28:00 GMT
 atossa genetics (nasdaq:atos) price target raised to $7.75  MarketBeat Mon, 22 Sep 2025 12:12:56 GMT
 Atossa Therapeutics (ATOS) Sees Analyst Rating Maintain; Price T  GuruFocus Mon, 22 Sep 2025 10:04:52 GMT
 Atossa Therapeutics announces issuance of U.S. patent  MSN Thu, 18 Sep 2025 10:29:22 GMT
 Atossa Therapeutics Appoints CORE IR for Investor  GlobeNewswire Wed, 17 Sep 2025 07:00:00 GMT
 craig-hallum maintains atossa therapeutics(atos.us) with buy rating  富途牛牛 Thu, 11 Sep 2025 13:31:00 GMT
 atossa therapeutics has requested type c meeting with u.s. fda  TipRanks Tue, 09 Sep 2025 08:48:45 GMT
 Atossa Therapeutics Announces New Regulatory Strategy  TipRanks Mon, 08 Sep 2025 07:00:00 GMT
 Atossa at H.C. Wainwright: Zinhoxifen’s Dual Pathway Strategy  Investing.com Mon, 08 Sep 2025 07:00:00 GMT
 atossa therapeutics has requested type c meeting with u.s. fda  TipRanks Mon, 08 Sep 2025 07:00:00 GMT

Atossa Therapeutics, Inc
(NASDAQ:ATOS) 

ATOS stock logo

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cance...

Founded: 2008
Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends